Switzerland
About Novartis AG
Novartis AG is a global pharmaceutical company headquartered in Basel, Switzerland. Founded in 1996, the company specializes in the research, development, manufacturing, and distribution of innovative medicines across multiple therapeutic areas.
Key Products
- Entresto – Treats chronic heart failure with reduced ejection fraction (HFrEF).
- Cosentyx – Used for plaque psoriasis, psoriatic arthritis, and ankylosing spondylitis.
- Kisqali – A selective CDK4/6 inhibitor for cancer treatment.
- Promacta/Revolade – Addresses immune thrombocytopenia (ITP) and severe aplastic anemia (SAA).
- Tafinlar + Mekinist – Oral combination therapy for specific cancers.
- Jakavi – Treats myelofibrosis, polycythemia vera, and graft-versus-host disease (GvHD).
- Zolgensma – A gene therapy for spinal muscular atrophy.
- Leqvio – Reduces LDL cholesterol in collaboration with Alnylam Pharmaceuticals.
Therapeutic Focus Areas
- Cardiovascular, Renal & Metabolic Diseases
- Immunology
- Neuroscience
- Oncology & Hematology
Partnerships & Collaborations
Novartis has a strategic collaboration with Alnylam Pharmaceuticals for the development and commercialization of Leqvio (inclisiran), an LDL cholesterol-lowering therapy.
The company continues to innovate in pharmaceuticals, delivering life-changing treatments to patients worldwide.
